Global Adoptive Cell Therapy Market Gaining Momentum amid Rising Occurrence of Cancer

Adoptive Cell Therapy Market

 Market Overview:

Adoptive cell therapy involves extracting immune cells from a patient and genetically modifying them to target specific diseases, such as cancer. It is an advanced form of immunotherapy that employs the transfer of immune cells with targeted cancer-fighting properties into patients. This helps boost the patient's immune cells to better identify and attack cancer cells. Adoptive cell therapy provides several advantages over conventional treatment options. It has relatively fewer side effects and offers long-lasting results. The demand for adoptive cell therapies is rising due to the increasing prevalence of cancer worldwide and limited success with traditional therapies.

Market key trends:

One of the major trends in the adoptive cell therapy market is the rising focus on developing "off-the-shelf" or allogeneic CAR T-cell therapies. This involves the development of CAR T-cell therapies that do not need to be individually manufactured per patient. This makes them more convenient and affordable for treating more patients. Another key trend is the rapidly growing focus on developing CAR T-cell therapies for solid tumors. Nearly 90% of clinical trials for CAR T-cell therapies currently focus only on blood cancers. However, research efforts are underway to make them more effective against solid tumors as well. Additionally, companies are focusing on engineering T-cells with novel binding domains for improved targeting ability and enhanced persistence and proliferation in the body. This is expected to increase the success rate of CAR T-cell therapies.

Porter’s Analysis

Threat of new entrants: The Adoptive Cell Therapy Market Demand requires high capital investment for R&D which poses high entry barriers for new players.

Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative treatment options. However, the rise in demand for personalized medicine increases their bargaining power.

Bargaining power of suppliers: Key raw material suppliers including cell culture media, serum, and reagents have moderate bargaining power. Established suppliers can influence prices.

Threat of new substitutes: Alternatives like gene therapy, chemotherapy pose minimal threat currently due to limited success and adoption. Cell therapy substitutes may pose high threat in long run.

Competitive rivalry: The market sees fierce competition among major players to gain FDA approvals and market share. Partnerships and collaborations are common to expand services globally.

Key Takeaways

The global adoptive cell therapy market is expected to witness high growth, exhibiting CAGR of 21.5% over the forecast period, due to increasing incidence of cancer globally. Rising awareness about personalized medicine and cell therapies is fueling the market demand.

The US dominates the adoptive cell therapy market owing to high adoption of advanced therapies and presence of leading market players. Asia Pacific is poised to be the fastest growing market due to increasing healthcare expenditure and rising Cancer incidence in the region.

Key players operating in the adoptive cell therapy market are Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc.,Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc.,Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs. Major players are focused on gaining regulatory approvals and expanding their services across markets.

Read More:

https://www.dailyprbulletin.com/adoptive-cell-therapy-market-demand-growth-and-share/